Articles by tag: sclc

ADC drugs against resistant small cell lung cancer: breakthrough 2026

New class of ADC drugs targets DLL3 and B7-H3, overcoming SCLC resistance. Analysis of efficacy, toxicity, and treatment prospects. Read more.

Orphan status of combination for lung cancer treatment: new EMA approach

European Commission granted orphan status to Zepzelca combination with atezolizumab for lung cancer. Learn how EMA reform changes rules for SCLC and who benefits from this decision. Detailed analysis.